Introducing ADI’s new CEO: Dr. Faith Mwangi-Powell
ADI announces our new CEO, joining on 1 October 2026
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
ADI announces our new CEO, joining on 1 October 2026
In this guest article, ADI Board Member and dementia advocate, Bill Yeates, shares his post diagnosis journey, discussing the hopes and challenges of life between scans.
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.
As 2021 comes to an end, ADI CEO Paola Barbarino reflects on the work of ADI in 2021 and what we are looking towards to in 2022.
The Dementia Alliance International (DAI) Environmental Design Special Interest Group (ED-SiG) is a newly established international advocacy group calling for implementations of designs that respect the dignity, autonomy, independence and equality of opportunity for people living with dementia.
To date, only 37 of 194 countries that signed up to implement the WHO Global action plan on dementia have created and funded national dementia plans. Our new campaign aims to galvanise and encourage more governments to develop national dementia plans following their 2017 commitment.
Earlier this year, Alzheimer’s Disease Association of the Philippines partnered with Memory Lane Games to build a culturally relevant and customised cognitive game app for carers and people living with dementia in the Philippines.
ADI hosted its first virtual regional meeting for ADI members in Latin America, since the COVID-19 pandemic began, on 12 November. The second virtual regional meeting Asia Pacific took place a week later on 12 November. During the Latin America meeting, 18 participants from 13 countries were in attendance. The 2-hour meeting…
The 'Building an inclusivity society' campaign from ADI member France Alzheimer aims to raise awareness amongst civil society and to dismantle stigmatic attitudes and ideas around dementia.
The news follows a negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting.